Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1Phase 1 1

Status

Recruiting 4Active not recruiting 1

Sponsor Class

OTHER 2NIH 2

Study Type

Interventional 4

Sponsor

Cancer Type

Sarcoma 4

Conditions

Prostatic Neoplasms 42Lung Neoplasms 39Leukemia, Myeloid, Acute 36Carcinoma, Non-Small-Cell Lung 33Neoplasm Metastasis 29Breast Neoplasms 28Myelodysplastic Syndromes 20Lymphoma, Large B-Cell, Diffuse 20Leukemia, Lymphocytic, Chronic, B-Cell 19Colorectal Neoplasms 19Pancreatic Neoplasms 18Precursor Cell Lymphoblastic Leukemia-Lymphoma 16Multiple Myeloma 15Triple Negative Breast Neoplasms 14Ovarian Neoplasms 14Glioblastoma 14Carcinoma, Renal Cell 13Burkitt Lymphoma 13Squamous Cell Carcinoma of Head and Neck 12Urinary Bladder Neoplasms 10Melanoma 10Lymphoma, Mantle-Cell 10Endometrial Neoplasms 10Carcinoma, Hepatocellular 10Myeloproliferative Disorders 9Mouth Neoplasms 9Leukemia, Myelomonocytic, Chronic 9Carcinoma 9Brain Neoplasms 9Oropharyngeal Neoplasms 8

Interventions

Specimen Handling 4Gemcitabine 3Doxorubicin 3liposomal doxorubicin 2Trabectedin 2Magnetic Resonance Spectroscopy 2Dacarbazine 2Biopsy 2toripalimab 1regorafenib 1peposertib 1cemiplimab 1anlotinib 1abemaciclib 1X-Rays 1Tretinoin 1Tissue Banks 1Tablets 1Surgical Procedures, Operative 1Standard of Care 1Rosuvastatin Calcium 1Radiotherapy 1Quality of Life 1Nivolumab 1Neoadjuvant Therapy 1Midazolam 1Injections 1Immunoglobulin G 1Ifosfamide 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Recruiting × Leiomyosarcoma × Specimen Handling × Clear all
NCT05711615 2026-05-15

Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma

National Cancer Institute (NCI)

Phase 1 Recruiting
30 enrolled
Sarcoma

Leiomyosarcoma, Liposarcoma, Sarcoma, Sarcoma, Synovial, Dermatofibrosarcoma, Histiocytoma, Malignant Fibrous

NCT06498648 2026-05-13

Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma

National Cancer Institute (NCI)

Phase 1/2 Recruiting
74 enrolled
Sarcoma

Leiomyosarcoma, Liposarcoma, Sarcoma

NCT06571734 2026-01-09

XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable Leiomyosarcoma

Northwestern University

Phase 2 Recruiting
29 enrolled
Sarcoma

Leiomyosarcoma

NCT06528769 2025-09-30

Study of All-Trans Retinoic Acid (ATRA) and Cemiplimab in Patients With Advanced Leiomyosarcoma

Ohio State University Comprehensive Cancer Center

Phase 2 Recruiting
16 enrolled
Sarcoma

Leiomyosarcoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡